# Peter Harris

> Peter Harris is a seed investor backing Life Science, Biotechnology and Health Diagnostics. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Total investments: 2
- Last investment: Feb 2022
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://es.linkedin.com/in/peter-harris-5a1b446

Peter Harris is a seed investor focused on Life Science and Biotechnology. Peter Harris

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.4M–$5M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Life Science | 1 | 50% |
| Biotechnology | 1 | 50% |
| Health Diagnostics | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CND Life Sciences | CND Life Sciences develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy. CND launched the Syn-One Test, a commercially available test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid inthe confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF).CND has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field. | $5M | Seed | Feb 01, 2022 |  |
| CND Life Sciences | CND Life Sciences develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy. CND launched the Syn-One Test, a commercially available test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid inthe confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF).CND has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field. | $2.4M | Seed | Jan 19, 2021 |  |

2 of 2 investments shown.

## Co-investors
- [HonorHealth](https://shizune.co/investors/profile/honorhealth) — VC Fund, 2 deals together
- [Cambrian Capital Partners](https://shizune.co/investors/profile/cambrian-capital-partners) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## Featured in investor lists
- [Life Science Angel Investors](https://shizune.co/investors/life-science-angel-investors)

## FAQ

### What does Peter Harris invest in?

Peter Harris invests primarily in Life Science, Biotechnology and Health Diagnostics startups, most often at Seed stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Peter Harris's check size?

Peter Harris typically joins rounds of $2.4M–$5M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Peter Harris participates in.

### When did Peter Harris last invest?

The most recent investment recorded for Peter Harris closed in Feb 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co